Souhaitez-vous accéder aux communiqués récents ?

- Company to Host Conference Call and Webcast Today at 8:30 a.m. EST – - Announces patient enrollment completed in Phase 2 of Phase 1/2 clinical trial for FCX-007 for recessive dystrophic...

Santa Monica, CA, Nov. 13, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...

Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early...

WATERLOO, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Client Outlook Inc. and Mach7 Technologies (Mach7) announced today they have been selected to spearhead Sentara Healthcare’s PACS Modernization...

Pivotal protocol for PRO 140 monotherapy trial to be filed with FDA in 2018 Once-weekly simple subcutaneous injections replaces HAART for certain HIV-infected patients Phase 3 PRO 140 HIV...

GAITHERSBURG, Md., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced several management promotions. “We are pleased to announce several key management promotions to...

Santa Monica, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal...

SALT LAKE CITY, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 studies will be featured at the San Antonio...

AMES, Iowa, Nov. 09, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of Cancer...

EDMONTON, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Capital Power (TSX: CPX) is proud to once again be recognized by the Canadian Electricity Association (CEA) for its 2017 safety performance at...